UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin
A quarter of patients fail to stomach survodutide.
Spotlight – Travere trips up but others are following in rare kidney disease
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.